Diabetes and Overexpression of proNGF Cause Retinal Neurodegeneration via Activation of RhoA Pathway

• Mohammed M. H. Al-Gayyar ,

  Contributed equally to this work with: Mohammed M. H. Al-Gayyar, Barbara A. Mysona

  Current address: Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura City, Egypt

  Affiliations Program in Clinical and Experimental Therapeutics. College of Pharmacy, University of Georgia, Athens, Georgia, United States of America, Vision Discovery Institute, Georgia Health Sciences University, Augusta, Georgia, United States of America, Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia

  ⨯
• Barbara A. Mysona ,

  Contributed equally to this work with: Mohammed M. H. Al-Gayyar, Barbara A. Mysona

  Affiliations Program in Clinical and Experimental Therapeutics. College of Pharmacy, University of Georgia, Athens, Georgia, United States of America, Vision Discovery Institute, Georgia Health Sciences University, Augusta, Georgia, United States of America, Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia

  ⨯
• Suraporn Matragoon,

  Affiliations Program in Clinical and Experimental Therapeutics. College of Pharmacy, University of Georgia, Athens, Georgia, United States of America, Vision Discovery Institute, Georgia Health Sciences University, Augusta, Georgia, United States of America, Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia

  ⨯
• Mohammed A. Abdelsaid,

  Affiliations Program in Clinical and Experimental Therapeutics. College of Pharmacy, University of Georgia, Athens, Georgia, United States of America, Vision Discovery Institute, Georgia Health Sciences University, Augusta, Georgia, United States of America, Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia

  ⨯
• Mona F. El-Azab,

  Current address: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Ismaileya, Egypt

  Affiliations Program in Clinical and Experimental Therapeutics. College of Pharmacy, University of Georgia, Athens, Georgia, United States of America, Vision Discovery Institute, Georgia Health Sciences University, Augusta, Georgia, United States of America, Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia

  ⨯
• Ahmed Y. Shanab,

  Affiliations Program in Clinical and Experimental Therapeutics. College of Pharmacy, University of Georgia, Athens, Georgia, United States of America, Vision Discovery Institute, Georgia Health Sciences University, Augusta, Georgia, United States of America, Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia

  ⨯
• Yonju Ha,

  Affiliations Department of Cell Biology and Anatomy, Georgia Health Sciences University, Augusta, Georgia, United States of America, Vision Discovery Institute, Georgia Health Sciences University, Augusta, Georgia, United States of America

  ⨯
• Sylvia B. Smith,

  Affiliations Department of Cell Biology and Anatomy, Georgia Health Sciences University, Augusta, Georgia, United States of America, Department of Ophthalmology, Georgia Health Sciences University, Augusta, Georgia, United States of America, Vision Discovery Institute, Georgia Health Sciences University, Augusta, Georgia, United States of America

  ⨯
• Kathryn E. Bollinger,

  Affiliation Vision Discovery Institute, Georgia Health Sciences University, Augusta, Georgia, United States of America

  ⨯
• Azza B. El-Remessy

  * E-mail: aelremessy@georgiahealth.edu

  Affiliations Program in Clinical and Experimental Therapeutics. College of Pharmacy, University of Georgia, Athens, Georgia, United States of America, Department of Pharmacology and Toxicology, Georgia Health Sciences University, Augusta, Georgia, United States of America, Department of Ophthalmology, Georgia Health Sciences University, Augusta, Georgia, United States of America, Vision Discovery Institute, Georgia Health Sciences University, Augusta, Georgia, United States of America, Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia

  ⨯